The P/E ratio of BeiGene is -six.sixty, meaning that its earnings are detrimental and its P/E ratio cannot be as compared to corporations with constructive earnings.
Should the serum and urine M-protein are unmeasurable,five a > fifty% reduce in the difference between included and uninvolved FLC levels is needed instead of the M-protein standards
The business is scheduled to release its following quarterly earnings announcement on Thursday, November third 2022.
We use cookies to understand how you employ our web site and also to increase your knowledge. This contains personalizing content material and advertising. To learn more, Click this link. By continuing to utilize our web page, you settle for our usage of cookies, revised Privateness Coverage and Phrases of Assistance.
Signal-as much as get the most recent news and scores for BeiGene and its competitors with MarketBeat's FREE each day e-newsletter.
MarketBeat won't deliver individualized economical guidance and will not concern recommendations or offers to buy inventory or offer any safety.
Be a part of an exceptional Neighborhood of traders who get cost-free briefings from Zacks' EVP Kevin Matras. Every single morning, he’ll go over certain elements that can effects the economic outlook and how you can capitalize on current market developments in true time.
Detrimental immunofixation to the serum and urine and disappearance of any smooth tissue plasmacytomas and < five% plasma cells in bone marrow3
Revlimid, also referred to as lenalidomide, is definitely an oral drug that's used for the procedure of various myeloma. It is a component of a class of prescription drugs identified as immunomodulatory medications (IMiDs), which perform towards most cancers cells partly by supporting the function of your immune technique.
5 Wall Avenue analysis analysts have issued "get," "keep," and "provide" rankings for BeiGene in the final 12 months. There are at this time 1 maintain ranking and four acquire scores for the stock. The consensus among the Wall Street investigation analysts is the fact that buyers should "acquire" BGNE shares.
Indicator-as many as acquire the most up-to-date information and ratings for BeiGene and its competitors with MarketBeat's Totally free everyday publication.
Seeking new inventory Thoughts? Wish to see which stocks are going? Watch our whole suite of economic calendars and industry information tables, all at no cost.
Be part of an exclusive Local community of investors who get free briefings from Zacks' EVP Kevin Matras. Each individual morning, he’ll explore certain things which will effect the financial outlook and tips on how to capitalize on industry developments in serious time. See:
BeiGene, Ltd., a biotechnology business, concentrates on getting, producing, producing, and commercializing numerous medicines around the world. Its products and solutions consist of BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat numerous myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat huge mobile tumor of bone; BLINCYTO to deal with acute lymphoblastic leukemia; KYPROLIS to deal with R/R several myeloma; SYLVANT to treat idiopathic multicentric castleman illness; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of assorted stable tumors; and Pobevcy to deal with metastatic colorectal cancer, liver cancer, and non-little mobile lung cancer (NSCLC). The organization's clinical phase drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-one antibody to take care of reliable and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and read more endometrial most cancers; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, as well as other good tumors.
The definitions of relapse, scientific relapse and relapse from CR will not be for use in calculation of time to development or development-free of charge survival.
MarketRank is calculated as a mean of obtainable group scores, with excess excess weight presented to Investigation and valuation.